Triglyceride metabolism pathway enzymes

The triglyceride metabolism pathway encompasses a series of enzymatic reactions responsible for the synthesis, storage, and breakdown of triglycerides (also called triacylglycerols), which are the main form of fat storage in humans. This pathway includes numerous enzymes such as acyl-CoA synthetases, glycerol-3-phosphate acyltransferases (GPATs), acylglycerophosphate acyltransferases (AGPATs), diacylglycerol acyltransferases (DGAT1, DGAT2, and DIESL/TMEM68), and enzymes for triglyceride hydrolysis in lipolysis including lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL). These enzymes can be individually targeted for therapeutic purposes in metabolic and cardiovascular diseases, but "triglyceride metabolism pathway enzymes" as a group does not constitute a single therapeutic target. Additional essential context: - Examples of individual therapeutic targets within this pathway (true therapeutic targets) include: Diacylglycerol O-acyltransferase 1 (DGAT1), Diacylglycerol O-acyltransferase 2 (DGAT2), Lipoprotein lipase (LPL), Hormone-sensitive lipase (HSL), Glycerol-3-phosphate acyltransferases (GPATs), Acyl-CoA synthetase long chain family members (ACSL3, ACSL5, etc.). - Therapeutic drugs such as DGAT inhibitors, fibrates (PPARα agonists), and niacin exert effects on specific enzymes within this pathway. - Enzymes in this pathway are highly regulated by metabolic state, hormones (insulin, glucagon, catecholamines), and transcription factors (SREBPs, PPARs). Summary: "Triglyceride metabolism pathway enzymes" is not a single therapeutic target but a collective group referred to in pathway biology. For structured target information, specific enzyme names (e.g., "Diacylglycerol O-acyltransferase 1") that make up this pathway, each of which may be an individual drug target, should be used.

Other names

triglyceride metabolic enzymesTG metabolism enzymestriacylglycerol metabolism enzymes